3 recruiting, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Teclison Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill - Colorectal Cancer; Lung Cancer | Phase 2 | Recruiting | Teclison Ltd. | 110 | 2021-05-20 | 2026-04-16 |
| TATE Versus TACE in Intermediate Stage HCC Tirapazamine, Doxorubicin - Carcinoma, Hepatocellular | Phase 2 | Terminated | Teclison Ltd. | 6 | 2017-12-05 | 2024-11-22 |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer Nivolumab Injectable Product, Trans-arterial tirapazamine embolization - Hepatocellular Carcinoma, Gastric Cancer | Phase 2 | Recruiting | Teclison Ltd. | 54 | 2017-07-01 | 2026-04-16 |
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Tirapazamine, Conventional Transarterial Embolization (TAE) - Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Teclison Ltd. | 25 | 2014-09-01 | 2026-04-20 |
Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (1) · Disease Progression (1) · Hypoxia (1) · Lung Neoplasms (1) · Neuroendocrine Tumors (1) · Stomach Neoplasms (1)
Tirapazamine (2) · Doxorubicin (1) · Ethiodized Oil (1) · Nivolumab (1) · pembrolizumab (1) · regorafenib (1) · trifluridine tipiracil drug combination (1)
United States (4) · Taiwan (1)
Michael Soulen, MD (1) · Nadine Abi-Jaoudeh (1) · Nadine Abi-Jaoudeh, MD (1) · Ray Lee (1)